Beyond glycemic control: Cardiovascular effects of incretin-based therapies

Frontiers of Hormone Research

Volumn 43, Issue , 2014, Pages 144-157

  Angeli, Franca S ^a   Shannon, Richard P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; CARDIOTONIC AGENT; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE 1 (7-36)AMIDE; GLUCAGON-LIKE PEPTIDE 1 (7-37); GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE BLOOD LEVEL; PEPTIDE FRAGMENT;

AMINO ACID SEQUENCE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL TONE; BRAIN ISCHEMIA; CARDIOVASCULAR EFFECT; CHEMICAL MODIFICATION; CHRONOTROPISM; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; GLYCEMIC CONTROL; HEART DISEASE; HEART EJECTION FRACTION; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HEART RATE; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS (TOPIC); NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC VASCULAR RESISTANCE; AGONISTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HEART; METABOLISM; PHYSIOLOGY;

BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HEART; HUMANS; INCRETINS; PEPTIDE FRAGMENTS; RECEPTORS, GLUCAGON;

EID: 84923575518     PISSN: 03013073     EISSN: 16623762     Source Type: Book Series    
DOI: 10.1159/000360598     Document Type: Article

References (30)

1. Fox CS, Coady S, Sorlie PD, Levy D, Meigs JB, D'Agostino RB Sr, Wilson PW, Savage PJ: Trends in cardiovascular complications of diabetes. JAMA 2004; 292: 2495-2499.
2. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P: Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009; 339:b4731.
3. Fineman MS, Cirincione BB, Maggs D, Diamant M: GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab 2012; 14: 675-688.
4. Monami M, Dicembrini I, Martelli D, Mannucci E: Safety of dipeptidyl peptidase-4 inhibitors: a metaanalysis of randomized clinical trials. Curr Med Res Opin 2011; 27(suppl 3):57-64.
5. Salcedo I, Tweedie D, Li Y, Greig NH: Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol 2012; 166: 1586-1599.
6. Ussher JR, Drucker DJ: Cardiovascular biology of the incretin system. Endocr Rev 2012; 33: 187-215.
7. Angeli FS, Shannon RP: Incretin based therapies: can we achieve glycemic control and cardioprotection. J Endocrinol 2013, Epub ahead of print.
8. Shannon RP, Angeli FS: Beyond glucose: cardiovascular effects of incretins and dipeptidyl peptidase-4 substrates. Eur Heart J Suppl 2012; 14:B14-B21.
9. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M: Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptordependent and-independent pathways. Circulation 2008; 117: 2340-2350.
10. Drucker DJ: The biology of incretin hormones. Cell Metab 2006; 3: 153-165.
11. Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L: Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011; 10: 22.
12. White WB, Pratley R, Fleck P, Munsaka M, Hisada M, Wilson C, Menon V: Cardiovascular safety of the dipeptidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab 2013; 15: 668-673.
13. Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ: Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012; 11: 3.
14. Frederich R, Alexander JH, Fiedorek FT, Donovan M, Berglind N, Harris S, Chen R, Wolf R, Mahaffey KW: A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010; 122: 16-27.
15. Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H, Musser BJ, Davies MJ, Kaufman KD, Goldstein BJ: Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010; 10: 7.
16. Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W: Assessing the cardiocerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large phase III type 2 diabetes population. Diabetes Obes Metab 2010; 12: 485-494.
17. Marso SP, Lindsey JB, Stolker JM, House JA, Martinez Ravn G, Kennedy KF, Jensen TM, Buse JB: Cardiovascular safety of liraglutide assessed in a patientlevel pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res 2011; 8: 237-240.
18. Cernea S, Raz I: Therapy in the early stage: incretins. Diabetes Care 2011; 34(suppl 2):S264-S271.
19. Bullock BP, Heller RS, Habener JF: Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996; 137: 2968-2978.
20. Knudsen LB, Pridal L: Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996; 318: 429-435.
21. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E: Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014; 16: 38-47.
22. McMurray JJ: The Vildagliptin in Ventricular Dysfunction Diabetes (VIVIDD) trial. Heart Failure Congress 2013, European Society of Cardiology, Lisbon.
23. Read PA, Hoole SP, White PA, Khan FZ, O'Sullivan M, West NE, Dutka DP: A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ Cardiovasc Interv 2011; 4: 266-272.
24. Lønborg J, Vejlstrup N, Kelbæk H, Bøtker HE, Kim WY, Mathiasen AB, Jørgensen E, Helqvist S, Saunamäki K, Clemmensen P, Holmvang L, Thuesen L, Krusell LR, Jensen JS, Køber L, Treiman M, Holst JJ, Engstrøm T: Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012; 33: 1491-1499.
25. Lonborg J, Kelbæk H, Vejlstrup N, Bøtker HE, Kim WY, Holmvang L, Jørgensen E, Helqvist S, Saunamäki K, Terkelsen CJ, Schoos MM, Køber L, Clemmensen P, Treiman M, Engstrøm T: Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv 2012; 5: 288-295.
26. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP: Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006; 12: 694-699.
27. Thrainsdottir I, Malmberg K, Olsson A, Gutniak M, Rydén L: Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab Vasc Dis Res 2004; 1: 40-43.
28. Halbirk M, Nørrelund H, Møller N, Holst JJ, Schmitz O, Nielsen R, Nielsen-Kudsk JE, Nielsen SS, Nielsen TT, Eiskjaer H, Bøtker HE, Wiggers H: Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol 2010; 298:H1096-H1102.
29. Shannon RP: DPP-4 inhibition and neuroprotection: do mechanisms matter? Diabetes 2013; 62: 1029-1031.
30. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al: Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987;76;142-154.